Tratamiento de psoriasis en adultos

Abstract

Introduction: Psoriasis is a chronic inflammatory skin disease that appears in the second to fourth decade of life. The exact cause of this pathology is unknown, but it can be caused by genetic and environmental factors, causing epidermal hypertrophy. Treatment options vary according to the severity of the condition. Objective: To determine psoriasis treatment in adults through an analysis of the latest literature reviews. Methodology: An exhaustive review of the updated bibliography published in high-impact scientific journals over the last five years in will be performed, selecting the data through the PRISMA method. Results: According to the treatment studies, it has been demonstrated that in mild cases, topical medications such as Betamethasone Dipropionate plus calcipotriol, tacrolimus 0.1% ointment, and Clobetasol cream are used, indicating a decrease in Psoriasis Area Severity Index (PASI) and recovery of erythema and desquamation. In moderate to severe cases, systemic and biological treatments are used, showing a PASI of 73.8% with Ustekinumab, a PASI of 75% with Apremilast, etarnercept, brodalumab and Tildrakizumab, a PASI of 74.6-82.8% with Certolizumab, a PASI of 78% with Infliximab, a PASI of 80-90% with Cyclosporine, and finally a PASI of 90% with Secukinumab, Guselkumab, and Risankizumab. Conclusion: According to the severity scales, treatment is multivariate. Mild forms often respond will to topical corticosteroids like a combination of betamethasone dipropionate plus calcipotriol. In moderate to severe psoriasis, anti-interleukin 17 and 23 are used, which are new drugs achieving successful outcomes.